Troy Cox - 28 Jun 2024 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Role
Director
Signature
/s/ Troy Cox by Agnieszka Gallagher, Attorney-in-Fact
Issuer symbol
LAB
Transactions as of
28 Jun 2024
Net transactions value
$0
Form type
4
Filing time
02 Jul 2024, 17:19:51 UTC
Previous filing
09 Jan 2024
Next filing
12 Dec 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LAB Common Stock Award $0 +43,128 +36% $0.000000 161,820 28 Jun 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LAB Stock Option (Right to buy) Award $0 +72,213 $0.000000 72,213 28 Jun 2024 Common Stock 72,213 $1.77 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 28, 2025 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.
F2 The Reporting Person declined and forfeited the 79,412 RSUs previously granted to the Reporting Person on January 5, 2024 in connection with the transactions contemplated by the Agreement and Plan of Merger, dated October 4, 2023, by and among Standard BioTools Inc., Martis Merger Sub, Inc. and SomaLogic, Inc.
F3 The Option becomes exercisable in twelve equal monthly installments beginning on July 28, 2024, subject to the Reporting Person's continued service through the applicable vesting date.